Semaglutide
Wegovy · Ozempic · Rybelsus · Novo Nordisk
What is Semaglutide?
Semaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist that mimics the GLP-1 hormone released in the gut in response to eating. It slows stomach emptying, reduces appetite, and helps regulate blood sugar. Clinical trials (STEP program) showed average weight loss of 15-17% over 68 weeks.
FDA Approval Status
FDA-approved: Wegovy for chronic weight management (2021), Ozempic for type 2 diabetes (2017), Rybelsus for type 2 diabetes (2019).
Dosing Schedule
Injection: 0.25mg once weekly for 4 weeks, then titrated up to 2.4mg. Oral (Rybelsus): 3mg daily titrated to 14mg.
Eligibility Criteria
Adults with BMI ≥30 kg/m², or BMI ≥27 kg/m² with at least one weight-related condition (type 2 diabetes, high blood pressure, or high cholesterol).
Common Side Effects
- Nausea (most common)
- Vomiting
- Diarrhea
- Constipation
- Stomach pain
- Headache
This is not a complete list. Discuss risks with your healthcare provider.